Print
|
Close
Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer
Active:
Yes
Cancer Type:
Lung Cancer
NCT ID:
NCT05676931
Trial Phases:
Phase II
Protocol IDs:
EDGE-Lung (primary)
NCI-2023-09840
2022-502916-35-00
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Gilead
NCI Full Details:
http://clinicaltrials.gov/show/NCT05676931
Summary
The purpose of this study is to assess the objective response rate (ORR) of
immunotherapy-based combination therapy and to assess the safety and tolerability of
immunotherapy-based combination therapy.
Treatment Sites in Georgia
City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.